| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2013-07-04 19:04:52 UTC |
|---|
| Update Date | 2021-09-14 15:00:01 UTC |
|---|
| HMDB ID | HMDB0060872 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Sorafenib beta-D-Glucuronide |
|---|
| Description | Sorafenib beta-D-Glucuronide belongs to the class of organic compounds known as n-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond. Sorafenib beta-D-Glucuronide is a moderately basic compound (based on its pKa). |
|---|
| Structure | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 InChI=1S/C27H24ClF3N4O9/c1-32-23(39)18-11-15(8-9-33-18)43-14-5-2-12(3-6-14)34-26(42)35(13-4-7-17(28)16(10-13)27(29,30)31)24-21(38)19(36)20(37)22(44-24)25(40)41/h2-11,19-22,24,36-38H,1H3,(H,32,39)(H,34,42)(H,40,41)/t19-,20-,21+,22-,24+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Sorafenib b-D-glucuronide | Generator | | Sorafenib β-D-glucuronide | Generator |
|
|---|
| Chemical Formula | C27H24ClF3N4O9 |
|---|
| Average Molecular Weight | 640.949 |
|---|
| Monoisotopic Molecular Weight | 640.118390708 |
|---|
| IUPAC Name | (2S,3S,4S,5R,6R)-6-{1-[4-chloro-3-(trifluoromethyl)phenyl][(4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phenyl)carbamoyl]amino}-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| Traditional Name | (2S,3S,4S,5R,6R)-6-{1-[4-chloro-3-(trifluoromethyl)phenyl][(4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phenyl)carbamoyl]amino}-3,4,5-trihydroxyoxane-2-carboxylic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
|---|
| InChI Identifier | InChI=1S/C27H24ClF3N4O9/c1-32-23(39)18-11-15(8-9-33-18)43-14-5-2-12(3-6-14)34-26(42)35(13-4-7-17(28)16(10-13)27(29,30)31)24-21(38)19(36)20(37)22(44-24)25(40)41/h2-11,19-22,24,36-38H,1H3,(H,32,39)(H,34,42)(H,40,41)/t19-,20-,21+,22-,24+/m0/s1 |
|---|
| InChI Key | HALZWBPBJOJUOZ-QMDPOKHVSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic oxygen compounds |
|---|
| Class | Organooxygen compounds |
|---|
| Sub Class | Carbohydrates and carbohydrate conjugates |
|---|
| Direct Parent | N-glucuronides |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1-n-glucuronide
- N-glucuronide
- Hexose monosaccharide
- Diaryl ether
- Glycosyl compound
- N-glycosyl compound
- N-phenylurea
- Trifluoromethylbenzene
- Pyridine carboxylic acid or derivatives
- 2-heteroaryl carboxamide
- Phenoxy compound
- Phenol ether
- Beta-hydroxy acid
- Chlorobenzene
- Halobenzene
- Pyridine
- Pyran
- Hydroxy acid
- Aryl chloride
- Oxane
- Monosaccharide
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Heteroaromatic compound
- Carboxamide group
- Urea
- Secondary carboxylic acid amide
- Secondary alcohol
- Carbonic acid derivative
- Carboxylic acid derivative
- Carboxylic acid
- Oxacycle
- Azacycle
- Ether
- Organoheterocyclic compound
- Polyol
- Monocarboxylic acid or derivatives
- Organochloride
- Organohalogen compound
- Organic nitrogen compound
- Alcohol
- Carbonyl group
- Organofluoride
- Organonitrogen compound
- Organopnictogen compound
- Alkyl fluoride
- Alkyl halide
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.4 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.7438 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.83 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1948.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 223.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 128.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 194.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 87.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 417.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 510.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 325.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 910.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 451.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1365.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 329.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 351.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 359.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 237.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 108.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Sorafenib beta-D-Glucuronide,1TMS,isomer #1 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4686.0 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TMS,isomer #2 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4660.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TMS,isomer #3 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4677.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TMS,isomer #4 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4665.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TMS,isomer #5 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4728.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TMS,isomer #6 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4471.3 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #1 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4633.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #10 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4616.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #11 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4640.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #12 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1 | 4417.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #13 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4622.3 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #14 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4406.0 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #15 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4427.9 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #2 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4633.0 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #3 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4622.2 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #4 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4652.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #5 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4422.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #6 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4607.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #7 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4616.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #8 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4627.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TMS,isomer #9 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4416.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #1 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4587.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #10 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4389.9 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #11 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4579.0 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #12 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4568.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #13 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4395.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #14 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4586.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #15 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1 | 4396.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #16 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4379.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #17 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4573.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #18 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1 | 4389.6 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #19 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4382.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #2 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4582.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #20 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4368.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #3 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4592.0 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #4 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4401.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #5 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1 | 4599.6 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #6 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C | 4604.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #7 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1 | 4405.9 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #8 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C | 4603.9 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,3TMS,isomer #9 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1 | 4397.6 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #1 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4849.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #2 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4841.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #3 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4847.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #4 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4859.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #5 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 4978.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,1TBDMS,isomer #6 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4653.8 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #1 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1 | 4970.9 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #10 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4965.3 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #11 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 5035.6 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #12 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4771.6 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #13 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 5047.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #14 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4780.5 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #15 | CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 4852.3 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #2 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4959.2 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #3 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4961.2 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #4 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 5039.7 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #5 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4766.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #6 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N1 | 4957.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #7 | CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4944.4 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #8 | CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C | 5026.1 | Semi standard non polar | 33892256 | | Sorafenib beta-D-Glucuronide,2TBDMS,isomer #9 | CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1 | 4762.1 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-9322163000-54fb357763970483dd0d | 2017-09-20 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_5) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_6) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_7) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_8) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_9) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_10) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_11) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_12) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_13) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_14) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_15) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-10-17 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Positive-QTOF | splash10-014i-0001904000-77afae7c5dd756d9a3f9 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Positive-QTOF | splash10-0lk9-1134900000-1bffc1070bb835e1fba3 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Positive-QTOF | splash10-0a4i-0133900000-71962cb0bba5f185f955 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Negative-QTOF | splash10-03dr-0151968000-0cc0bb024009b1d9b613 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Negative-QTOF | splash10-03di-0140950000-9e5b40a4b46a004f059c | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Negative-QTOF | splash10-0006-4792500000-a80511e6b557923dfacf | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Negative-QTOF | splash10-0kg9-0138139000-e1f389ba05fd6d003fba | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Negative-QTOF | splash10-0a4l-6110294000-e0f30f817ff676b5381f | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Negative-QTOF | splash10-0006-9713203000-71ac59636f4d397c3bae | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Positive-QTOF | splash10-00dl-0002109000-62f8e1c06fa311179cfa | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Positive-QTOF | splash10-014i-0000933000-35c30825c89c1f04e4af | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Positive-QTOF | splash10-069c-0321942000-844e398ad2337b1e0e04 | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|